Clinical Trials
7 trialsNCT02943642 2026-05-18
Resimmune®
Virogen Biotechnology Inc.
Phase 2 Withdrawn
NCT01587352 2026-04-13
Vorinostat in Treating Patients With Metastatic Melanoma of the Eye
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03713320 2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2 Terminated
NCT00121225 2019-01-29
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00958074 2018-10-18
Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma
University of Washington
Phase 2 Terminated
NCT00091559 2017-04-05
Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00810576 2012-08-07
Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Phase 2 Terminated